Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Jounce Therapeutics, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Jounce Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Jounce Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is JNCE. The reporting company's CIK number is 1640455.
The total value of stock buying since 2005 is $10,187,200.
The total value of stock sales since 2005 is $100,000.
The total value of stock option exercises since 2005 is $16,840.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2018-01-26||Duncan Barbara Gayle||Sale||4,000||25.00||100,000|
|2018-01-26||Duncan Barbara Gayle||Option Ex||4,000||4.21||16,840|
|2017-02-01||Higgons John Duncan (Director)||Buy||6,700||16.00||107,200|
|2017-02-01||Karsen Perry A (Director)||Buy||5,000||16.00||80,000|
|2017-02-01||Celgene Corp /de/ (10% Owner)||Buy||625,000||16.00||10,000,000|
Insider trading activities including stock purchases, stock sales, and option exercises of JNCE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Jounce Therapeutics, Inc. (symbol JNCE, CIK number 1640455) see the Securities and Exchange Commission (SEC) website.